Clinical Trials

Inclusion Criteria:

• Written informed consent.
• Aged 18 or above.
• Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation.
• Documented PD-L1 expression by PD-L1 IHC per local report.
• Confirmed progression during treatment with a CPI-including regimen.
• ECOG performance status of 0 or 1 at enrolment.
• Life expectancy of ≥ 12 weeks at enrolment.
• Adequate bone marrow, liver and kidney function.

Exclusion Criteria:

• Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion.
• Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation).
• Previous treatment with an anti-TIGIT therapy.
• Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
• Primary or secondary resistance after treatment with 2 or more regimens including a CPI.
• Symptomatic central nervous system (CNS) metastasis.
• Thromboembolic event within 3 months prior to enrolment.
• Other invasive malignancy within 2 years prior to screening.

Eligibility last updated 7/7/22. Questions regarding updates should be directed to the study team contact.